Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      SHARx Analyzes TrumpRx: Transparency on Drug Costs Doesn't Resolve Pricing and Access Gatekeeping


      News provided by

      SHARx

      Mar 24, 2026, 11:39 ET

      Share this article

      Share this article


      The launch of the Trump administration's TrumpRx drug platform is renewing scrutiny of prescription drug costs. Beyond sticker shock, the mechanisms behind drug pricing and access come down to the complexity of pharmacy benefit manager (PBM) systems that control coverage, rules, and distribution.

      ST. LOUIS, March 24, 2026 /PRNewswire/ -- SHARx highlights that patient affordability and access are driven less by list prices alone and more by the systems governing coverage, approvals, and distribution, as the launch of the Trump administration's TrumpRx drug platform renews scrutiny of prescription drug costs.

      Lower drug list prices can generate headlines. But many of the decisions that shape what patients pay and whether they receive treatment occur inside the network of pharmacy benefit managers (PBMs) that sit between drug manufacturers, insurers, pharmacies and patients.

      Continue Reading
      “In most industries you can see the price of what you’re buying. With prescription drugs, the price is hidden in a maze of contracts most employers can’t even audit. If policymakers want real reform, they must find a way to break down this maze and address the incentives built into the middle of the system”
      “In most industries you can see the price of what you’re buying. With prescription drugs, the price is hidden in a maze of contracts most employers can’t even audit. If policymakers want real reform, they must find a way to break down this maze and address the incentives built into the middle of the system”

      "Lowering some drug pricing doesn't mean the patient will see a big difference," said Paul Pruitt, Chief Growth Officer of SHARx, a champion for affordable access to medications. "The real power sits in the system that decides whether the drug is approved by your insurer, which pharmacy you must use to get it, and how industry rebates are structured."

      The TrumpRx platform seeks to reduce prescription drug costs by expanding direct purchasing options and increasing pricing transparency. But most Americans still obtain medications through employer-sponsored insurance plans where PBMs determine coverage and reimbursement rules, according to reporting in The Hill.

      The PBM problem raises a growing question among policymakers and employers: Can drug price reform work if gatekeeping embedded in the system remains unchanged?

      The Hidden Gatekeepers of Drug Access

      PBMs manage prescription drug benefits for hundreds of millions of Americans. In theory, they negotiate discounts with pharmacies to reduce costs. In practice, they also control many of the system's most consequential decisions, including:

      • Which drugs are covered;
      • Which medications require prior authorization;
      • What price is paid at the pharmacy,
      • Which pharmacies patients are allowed to use; and
      • How rebates and fees flow through the supply chain

      A 2024 Federal Trade Commission report found that the largest PBMs now control most U.S. prescription drug claims, giving them significant influence over drug pricing and access.

      For patients, PBM authority often appears as administrative hurdles. Prior authorization rules, step therapy requirements and restricted pharmacy networks can delay treatment even when insurance technically covers the medication.

      "Coverage doesn't always mean access," Pruitt said. "You can have insurance; you can have a prescription, and you can still spend weeks fighting through approvals just to start therapy."

      Specialty Drugs Are Where the System Collides

      The tension between pricing and access becomes especially clear in the specialty drug market, where the medications to treat some of healthcare's most serious conditions, including cancer, autoimmune diseases, genetic disorders and transplant complications are accessed. Specialty Pharmacy Continuum recently reported specialty drugs also represent the fastest-growing segment of prescription drug spending. At the same time, insurers and PBMs often apply the strictest utilization controls to these therapies.

      Reporting in Drug Store News suggests PBMs may expand prior authorization requirements for certain high-cost specialty therapies. In some cases, patients must obtain these medications exclusively through specialty pharmacies owned by the same companies that manage their drug benefits.

      "Specialty drugs are where the financial incentives really collide and compound," Pruitt said. "Pricing, distribution, and approvals all run through the same system."

      Vertical Integration Raises Policy Questions

      Regulators have also increased scrutiny of the growing vertical integration among PBMs, insurers, and pharmacies. Many of the nation's largest PBMs now operate within large healthcare conglomerates that also own insurance companies and pharmacy networks.

      According to the Federal Trade Commission (FTC), PBMs sit "at the center of the complex pharmaceutical distribution chain," which gives them visibility and influence across multiple layers of the drug market. Critics say this structure can create overlapping financial incentives that employers and patients struggle to understand.

      "When the insurer, PBM, and pharmacy are owned by the same organization, it's like refereeing your own game," Pruitt said. "The same company can influence pricing, approvals, and where the drug is filled."

      The Employer Push Back Era

      Employers, who sponsor health coverage for more than half of Americans, are increasingly scrutinizing the pharmacy benefit system as prescription drug costs continue to rise. Many plan sponsors say their biggest challenge is understanding where their healthcare dollars go.

      Several media investigations into employer health plans have highlighted growing frustration among companies trying to untangle rebate structures and hidden fees embedded in the drug supply chain. Without transparency into contracting terms and rebate flows, employers often struggle to determine the true cost of medications.

      "You cannot meaningfully lower drug prices without addressing rebates," Pruitt said. "A significant portion of the list price is tied to the contracting system that sits between the manufacturer and the patient."

      Bigger Policy Questions

      The renewed focus on drug prices reflects decades of political pressure to hold pharmaceutical manufacturers accountable for the rising costs that many healthcare economists say are driven by the convoluted pharmaceutical supply chain.

      "In most industries you can see the price of what you're buying. With prescription drugs, the price is hidden in a maze of contracts most employers can't even audit. If policymakers want real reform, they must find a way to break down this maze and address the incentives built into the middle of the system," Pruitt said. "Otherwise, price cuts risk disappearing before they ever reach the patient."

      For patients with serious illnesses, the consequences are immediate, Pruitt noted. 

      "When someone with cancer or a rare disease needs medication, they are thrust into a system that feels like a multi-layered obstacle course of roadblocks, gatekeepers and red tape." Pruitt said. "But for many families, that's exactly what happens. For many patients and their doctors, the challenge is not about finding the right medicine. It's about surviving the levels bureaucracy to get and afford their medicine."

      About SHARx

      SHARx was founded to fight back against the broken system of overpriced prescription drugs. Industry pioneers Corey Durbin and Paul Pruitt built SHARx to put people before profits. With an innovative and ethical sourcing model, SHARx cuts through the waste with radical transparency, common-sense cost containment, and a member-first approach. No hidden markups. No games. Just the meds people need, delivered affordably, reliably, and with dignity. Learn more at: sharxplan.com

      References

      • Choi, J. (2026, Feb. 25). Trump lauds his online drug platform as prescription drug win. The Hill. thehill.com/policy/healthcare/5753853-prescription-drug-costs-trumprx-state-union/
      • Goldman, M. (2026, Feb. 25). Trump touts drug price reductions most Americans may not feel. Axios.
        axios.com/2026/02/25/trump-drug-prices-state-of-the-union
      • Federal Trade Commission. (2024, July 9). FTC interim staff report on pharmacy benefit managers. ftc.gov/news-events/news/press-releases/2024/07/ftc-interim-staff-report-pharmacy-benefit-managers
      • Shaw, G. (2026, Feb. 24). Higher-cost specialty therapies moving up. Specialty Pharmacy Continuum. specialtypharmacycontinuum.com/Online-First/Article/02-26/Higher-Cost-Specialty-Therapies-Moving-Up/79800
      • Levy, S. (2026, Feb. 26). CVS Caremark advances prior authorization for specialty medications. Drug Store News. drugstorenews.com/cvs-caremark-advances-prior-authorization-specialty-medications

      Media Inquiries: 
      Karla Jo Helms 
      JOTO PR™
      727-777-4629
      Jotopr.com  

      SOURCE SHARx

      Modal title

      Also from this source

      One Prescription Can Rewrite the Benefits Budget, SHARx Warns

      One Prescription Can Rewrite the Benefits Budget, SHARx Warns

      Many new prescriptions come with price tags that can eat up a large part of an employer's annual healthcare forecast. For self-funded employers,...

      Patent Expiration Does Not Signal a Savings Date, Cautions SHARx's Paul Pruitt

      Patent Expiration Does Not Signal a Savings Date, Cautions SHARx's Paul Pruitt

      A drug nearing patent expiration may seem like relief from high prices, but lower-cost competition can still take years to reach the market....

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Domestic Policy

      Domestic Policy

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.